Cell biology

Pharmaceutical and Biotechnology Companies Lead the Microcarrier Market with Innovation and R&D Investments

Retrieved on: 
Monday, October 16, 2023
Incidence, Reagent, Lead, Vaccine, Consumables, Regenerative medicine, Cell, Conditional sentence, Biotechnology, Bioreactor, Cancer, Diabetes, Rheumatoid arthritis, Tissue engineering, Institute of Information Technology Advancement, Environment, Research and development, Downstream processing, Research, Cell biology, Microcarrier, Media, Pharmaceutical industry, Veterinary medicine, Fine chemical, Growth

The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.

Key Points: 
  • The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.
  • Pharmaceutical and biotechnology companies lead the Microcarrier Market, relying extensively on microcarriers for various applications.
  • Continuous investments in research and development, along with innovation in microcarrier technology, further bolster the demand for microcarriers.
  • The United States stands out in the Microcarrier Market, known for its innovation and technological advancements.

John D. Carpten, Ph.D., City of Hope’s Chief Scientific Officer, Elected to Prestigious National Academy of Medicine

Retrieved on: 
Monday, October 9, 2023
Science, DEI (Diversity, Equity and Inclusion), Biotechnology, Research, Oncology, Health, Professional Services, Genetics, Morgan, Incidence, National Academy of Medicine, Multimedia, Beckman Research Institute, Medicine, City of Hope National Medical Center, Irell & Manella, Biology, Breast cancer, NAM, Multiple myeloma, Mortality, Irell & Manella Graduate School of Biological Sciences, Cancer, National academy, Diabetes, Patient, City, Workforce, City of Hope, Policy, Colorectal cancer, Cell biology, African Americans, Health equity, Prostate cancer, Genomics, Deana, National Cancer Institute, Dietary supplement, Vaccine, Management, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20231009647781/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231009647781/en/
    John D. Carpten, Ph.D., chief scientific officer at City of Hope, was presented with one of the highest honors in health and medicine on Oct. 9, 2023, when he was elected to the National Academy of Medicine.
  • Carpten has numerous national leadership roles and is the first African American to chair the National Cancer Institute’s National Cancer Advisory Committee.
  • Carpten is director of the National Cancer Institute-designated City of Hope comprehensive cancer center and director of Beckman Research Institute of City of Hope.
  • “I am deeply humbled to be elected a member of the National Academy of Medicine.

WhiteSwell Announces Successful Treatment of Acute Decompensated Heart Failure Patients in its Early Feasibility DELTA-HF Study

Retrieved on: 
Saturday, October 7, 2023
Health, Clinical Trials, Cardiology, Medical Devices, ADHF, Heart Failure Society of America, Lymphatic system, Acute decompensated heart failure, Feasibility, Risk, ICCU, Creatinine, Ohio State University Wexner Medical Center, Cell biology, Congestion, Ohio State University, Thoracic duct, Kidney, Heart failure, Safety, Patient, Tissue, Drainage, Pharmaceutical industry, Medical imaging, Physiology

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.
  • Nine hospitalized patients received eLym therapy in conjunction with diuretic therapy, while six patients received standard of care treatment with loop diuretics alone.
  • “It cannot be overemphasized how significant and challenging it is to fully decongest patients hospitalized with decompensated heart failure.

Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements

Retrieved on: 
Thursday, October 12, 2023
Acquisition, Target, Research, HT, Mass spectrometry, Health, Flow cytometry, Luminex, Collection, Biological specimen, Growth, Protein, Cell biology, Fine chemical, Online shopping, Discovery, EU

HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.
  • Alongside this relocation, the company's AllCells cell and gene therapy division has set up its new divisional headquarters in Alameda, California.
  • In addition, Discovery is introducing Olink Explore HT proteomic services and debuting an all-new digital platform.
  • With support from the State of Alabama and HudsonAlpha, Discovery has opened its new 93,000-square-foot global headquarters building in Huntsville.

Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements

Retrieved on: 
Thursday, October 12, 2023
Acquisition, Target, Research, HT, Mass spectrometry, Health, Flow cytometry, Luminex, Collection, Biological specimen, Growth, Protein, Cell biology, Fine chemical, Online shopping, Discovery, EU

HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.
  • Alongside this relocation, the company's AllCells cell and gene therapy division has set up its new divisional headquarters in Alameda, California.
  • In addition, Discovery is introducing Olink Explore HT proteomic services and debuting an all-new digital platform.
  • With support from the State of Alabama and HudsonAlpha, Discovery has opened its new 93,000-square-foot global headquarters building in Huntsville.

Miriam Merad, MD, PhD, Elected to the National Academy of Medicine for Seminal Work in Immunology and Cell Biology

Retrieved on: 
Monday, October 9, 2023
Neoplasm, Parent, Health, National Academy of Medicine, Icahn School of Medicine at Mount Sinai, Lung cancer, Doctor of Philosophy, Haematopoiesis, MS, National academy, Public, Mount Sinai Health System, NAM, Cell, Master of Science, Immunity, MPH, B cell, Medicine, Disease, Cancer, Inflammation, Freedom, Patient, Immunology, Immune system, Cell biology, Inflammatory bowel disease, Marc, Bangladesh Technical Education Board, Macrophage, NAS, Research, Vaccine, Pharmaceutical industry, MD, Nature, Immunotherapy, Science

NEW YORK, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.

Key Points: 
  • Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
  • NEW YORK, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
  • With this appointment, Dr. Merad joins an elite group of distinguished international scientists alongside 100 new members this year.
  • For more details, see this year's official announcement from the National Academy of Medicine: https://nam.edu/news/ .

Sony Announces Launch of FP7000 Spectral Cell Sorter Supporting High-Parameter Sorting with More Than 44 Colors(*1)

Retrieved on: 
Monday, October 9, 2023
Pressure, Fluorophore, Sony, Automation, PCR, Cell, Power source, Microfluidics, Calibration, 6-way, Flow cytometry, Subjectivity, Electronics, Laser, 4-way, Cell biology, Research, Microscope, Television, Fine chemical

TOKYO, Oct. 9, 2023 /PRNewswire/ -- Sony Corporation ("Sony") today announced the launch of FP7000 spectral cell sorter that supports high-speed, high-parameter sorting with more than 44 colors with simple workflows, leveraging its patented spectral technology-based optics, advanced electronics and fluidics.

Key Points: 
  • -Meeting the evolving needs in immunology, cell biology and oncology-
    TOKYO, Oct. 9, 2023 /PRNewswire/ -- Sony Corporation ("Sony") today announced the launch of FP7000 spectral cell sorter that supports high-speed, high-parameter sorting with more than 44 colors with simple workflows, leveraging its patented spectral technology-based optics, advanced electronics and fluidics.
  • The new high-parameter spectral cell sorter is configurable with up to 6 lasers and 182 detectors enabling the detection and sorting of cell populations of interest, using complex panels comprised of more than 44 colors.
  • FP7000 spectral cell sorter is scheduled to be available in autumn 2024.
  • Optical capability is matched to Sony's ID7000™ Spectral Cell Analyzer thus enabling multicolor assay portability from the cell analyzer to the cell sorter.

Orakl Oncology raises €3 million to develop its techbio platform for precision oncology

Retrieved on: 
Wednesday, October 4, 2023
Start-Up, Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Cell biology, Drug development, Neoplasm, Clinical trial, Cancer, College of Engineering (KNUST), Biomarker, Automation, Patient, Collection, Machine learning, Engineering, Drug discovery, Gustave Roussy, Biology, AI, Director general, Medical imaging, Pharmaceutical industry

Orakl Oncology , a precision oncology start-up, today announces that it has raised €3 million to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate oncology drug development.

Key Points: 
  • Orakl Oncology , a precision oncology start-up, today announces that it has raised €3 million to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate oncology drug development.
  • A major challenge in oncology is that drug candidates meet patients too late in the development process.
  • Dr. Fanny Jaulin, Orakl Oncology CEO & Co-Founder, commented, “Our ambition is to become a world-leading techbio platform leveraging the smartest collection of tumor avatars to transform oncology drug development and bring faster, smarter and more cost-effective treatments to patients.
  • They aim to disrupt precision oncology by leveraging major academic and pharma partnerships to accelerate drug development, ultimately leading to better patient outcomes."

Bruker Completes Acquisition of PhenomeX

Retrieved on: 
Tuesday, October 3, 2023
Medical Devices, Health, Genetics, Research, Science, Biotechnology, Genotype, Cell biology, BRKR, Cell, Corporation, Acquisition, EPS, Phenotype, Cryptocurrency, Mobile phone, Bruker, Optofluidics, Beacon

Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools, for $108 million in cash.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools, for $108 million in cash.
  • Bruker announced the agreement to acquire PhenomeX on August 17, 2023.
  • “We are excited to welcome PhenomeX to Bruker,” commented Dr. Mark R. Munch, President of the Bruker NANO Group.
  • During its Q3 2023 earnings release, Bruker will provide more details on the expected Q4 2023 effect from PhenomeX.

TWO BEAR CAPITAL OPENS NEW YORK HEADQUARTERS IN THE ALEXANDRIA CENTER FOR LIFE SCIENCE

Retrieved on: 
Monday, October 2, 2023
Oberlin College, Venture, Jerusalem Venture Partners, Biotechnology, SVB Securities, Alexandria Center of Arts, Part, Doctor of Philosophy, Suite, Bear, Genetics, Cell biology, Machine learning, Baylor College of Medicine, Growth, Contrary (venture capital firm), Ecosystem, AI, Institute for Healthcare Advancement, Computer science, Management, Biology

NEW YORK, Oct. 2, 2023 /PRNewswire/ -- Two Bear Capital, the venture capital firm investing in disruptors in biotechnology, bioinformatics, healthcare IT, machine learning and AI, and information security, today announced the opening of its New York headquarters within the Alexandria Center for Life Science in New York City. With a mission to create and grow the life sciences ecosystems and clusters that ignite and accelerate the world's leading innovators, the Alexandria Center is the ideal location from which Two Bear Capital will operate in New York.

Key Points: 
  • With a mission to create and grow the life sciences ecosystems and clusters that ignite and accelerate the world's leading innovators, the Alexandria Center is the ideal location from which Two Bear Capital will operate in New York.
  • Two Bear Capital is focused on harnessing life sciences and technology to solve the world's toughest challenges.
  • Mike Goguen, Founder and Managing Partner of Two Bear Capital said; "Opening the Two Bear Capital offices in New York represents a real milestone for our firm.
  • Two Bear Capital's New York headquarters are located at 430 East 29th Street, Suite 945, New York, NY 10016.